Full Press Release Details
ANDOVER, Mass.,July 21, 2026/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2026 after market close on Tuesday, August 4, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 6054544. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website athttps://investors.transmedics.com/.
About TransMedics Group, Inc.TransMedicsis the world's leader in portableextracorporealwarm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:Brian JohnstonGilmartin GroupInvestors@transmedics.com
SOURCE TransMedics Group, Inc.